Dr. Ford is our Chief Medical Officer. He is a co-founder and clinical development lead of Phraktion Limited. He has driven recruitment and randomization of ~1,500 IPF patients across several clinical studies.

Most recently Paul was the Senior VP of Clinical Development at PureTech (US) running the deupirfenidone program in IPF, long-COVID and lymphoedema.

Previously, a VP and Head of Respiratory Medicine at Galapagos (Belgium) running a P3 in IPF (published in JAMA) and GPR84 antagonist program in IPF. Galecto (Denmark), he was the Chief Medical Officer running their P2a in IPF. Paul has 10 years of academic research at Imperial College in London.